Apatinib: TKI Mechanism, Clinical Efficacy & Research Guide

Explore the mechanism, efficacy in gastric cancer and HCC, and future combination therapies of Apatinib (VEGFR-2 TKI) in this clinical research overview.

#apatinib#tyrosine-kinase-inhibitor#oncology#gastric-cancer#hcc#vegfr-2#cancer-research#angiogenesis

Apatinib: A Novel TKI

Mechanism, Clinical Efficacy, and Future Directions

Clinical Research Overview

abstract medical background with blue DNA strands and molecular structures clean white minimalist

Made by

Mechanism of Action

Apatinib is a small-molecule tyrosine kinase inhibitor (TKI) that highly selectively targets Vascular Endothelial Growth Factor Receptor-2 (VEGFR-2). By blocking this pathway, it effectively inhibits tumor angiogenesis—the process by which tumors grow new blood vessels to survive.

• Selective inhibition of VEGFR-2 tyrosine kinase activity.
• Blocks VEGF-mediated endothelial cell migration and proliferation.
• Decreases tumor microvessel density.

biological diagram of VEGFR-2 receptor inhibition on a cell membrane blocking angiogenesis signal pathway medical illustration

Made by

Chemical Properties & Structure

Apatinib chemical structure diagram 2D sketch black lines on white background

Small Molecule TKI

Oral Administration

Highly Potent binding affinity to VEGFR-2

Made by

Clinical Efficacy: Gastric Cancer

Phase III Trial Results (Li et al., J Clin Oncol 2016). Significant improvement in Overall Survival (OS) for advanced gastric cancer patients failing prior chemotherapy.

Approves by NMPA for 3rd-line treatment
Standard of care in China
Reduced risk of death significantly

Chart

Made by

Efficacy in Hepatocellular Carcinoma (HCC)

Results from the HELP Study (Qin et al., JAMA Oncol 2021). Apatinib serves as a viable option for patients with advanced HCC who progressed on first-line therapy.

Chart

Made by

Broad Spectrum Application

schematic illustration of lungs medical style blue tones

NSCLC
Studied in advanced non-squamous NSCLC showing prolonged PFS compared to placebo.

schematic illustration of breast tissue cells medical style blue tones

Breast Cancer
Showing potential in non-triple-negative metastatic breast cancer in later lines of therapy.

schematic illustration of ovaries medical style blue tones

Ovarian Cancer
Example: APPROVE trial. Apatinib combined with chemotherapy showed improved PFS.

Made by

Safety Profile & Adverse Events

Apatinib has a manageable toxicity profile, characteristic of VEGFR TKIs. Most adverse events (AEs) are mild to moderate and can be managed with dose interruptions or reductions.

Management

Monitor blood pressure weekly.
Check urine protein regularly.
Dose reduction recommended for Grade 3/4 toxicity.

Chart

Made by

Pharmacokinetics (PK)

Absorption (Tmax)

3 - 4 Hours

Half-life (t1/2)

~9 Hours

Metabolism

Hepatic (CYP3A4)

Excreted mainly via feces (approx 77%) and urine.

Made by

Synergy: Immunotherapy Combination

Apatinib normalizes tumor vasculature, thereby enhancing the infiltration of immune effector cells. This creates a synergistic effect when combined with PD-1 inhibitors (e.g., Camrelizumab).

"Anti-angiogenesis + Immunotherapy is the new frontier in solid tumor treatment."

Diagram showing synergy between anti-angiogenesis and immunotherapy T-cells attacking tumor

Made by

Key Takeaways

Mechanism

Highly selective VEGFR-2 inhibitor targeting tumor angiogenesis.

Indications

Proven efficacy in Gastric Cancer and HCC; promising in Lung, Breast, and Ovarian cancers.

Future

Combination therapies with immune checkpoint inhibitors represent the primary path forward.

Made by

DESIGNER-MADE
PRESENTATION,
GENERATED FROM
YOUR PROMPT

Create your own professional slide deck with real images, data charts, and unique design in under a minute.

Generate For Free